Revolution Medicines, Inc. (RVMD) NASDAQ

152.41

-11.2713(-6.89%)

Updated at June 02 01:47PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Mark A. Goldsmith	Chief Executive Officer, President & Chairman	1.71M	1962
Xiaolin Wang	Executive Vice President of Development	701,200	1970
Jeff Cislini	Senior Vice President, General Counsel & Corporate Secretary	791,750	1975
Jack Anders	Chief Financial Officer	874,133	1977
Margaret A. Horn	Chief Operating Officer	1.02M	1963
Stephen Kelsey Path. FRCP	President of Research & Development	1.09M	1961
Alan Bart Sandler	Chief Development Officer	0	1957
Ryan Asay	Senior Vice President of Corporate Affairs	0	N/A
Hieu Le	Vice President of Compliance	0	N/A
Erin Graves	Senior Director of Corporate Communications & Investor Relations	0	N/A
Zhengping Wang	Senior VP of Non-Clinical Development & Clinical Pharmacology	0	N/A
Carlos Escobar	VP & Head of Information Security	0	N/A
Martin D. Burke	Co-Founder & Chairman of Scientific Advisory Board	0	N/A
Michael A. Fischbach	Academic Co-Founder & Member of Scientific Advisory Board	0	1981
Adrian Gill	Executive VP & Head of Early Discovery	0	N/A
Jan Smith	Chief Scientific Officer	0	N/A
Kevan Shokat	Academic Co-Founder & Member of Scientific Advisory Board	0	N/A
Anthony Mancini	Chief Global Commercialization Officer	0	1971
Gerwin Winter	Senior VP & GM for the European region	0	N/A
Walter Reiher	Chief Information Officer	0	N/A

Name

Title

Pay

Year Born

Mark A. Goldsmith

Chief Executive Officer, President & Chairman

1.71M

1962

Xiaolin Wang

Executive Vice President of Development

701,200

1970

Jeff Cislini

Senior Vice President, General Counsel & Corporate Secretary

791,750

1975

Jack Anders

Chief Financial Officer

874,133

1977

Margaret A. Horn

Chief Operating Officer

1.02M

1963

Stephen Kelsey Path. FRCP

President of Research & Development

1.09M

1961

Alan Bart Sandler

Chief Development Officer

1957

Ryan Asay

Senior Vice President of Corporate Affairs

N/A

Hieu Le

Vice President of Compliance

N/A

Erin Graves

Senior Director of Corporate Communications & Investor Relations

N/A

Zhengping Wang

Senior VP of Non-Clinical Development & Clinical Pharmacology

N/A

Carlos Escobar

VP & Head of Information Security

N/A

Martin D. Burke

Co-Founder & Chairman of Scientific Advisory Board

N/A

Michael A. Fischbach

Academic Co-Founder & Member of Scientific Advisory Board

1981

Adrian Gill

Executive VP & Head of Early Discovery

N/A

Jan Smith

Chief Scientific Officer

N/A

Kevan Shokat

Academic Co-Founder & Member of Scientific Advisory Board

N/A

Anthony Mancini

Chief Global Commercialization Officer

1971

Gerwin Winter

Senior VP & GM for the European region

N/A

Walter Reiher

Chief Information Officer

N/A

Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.